Skip to main content
Clinical Trials/IRCT20180814040795N2
IRCT20180814040795N2
Recruiting
Phase 3

A comparative study on the effects of oral N-acetylcystein and Pregabalin on the blood level of oxidative stress biomarkers in patients with painful diabetic neuropathy: adouble_blinde randomized clinical trial.

Hamedan University of Medical Sciences0 sites140 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hamedan University of Medical Sciences
Enrollment
140
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age 30 to 70 years old
  • History of type 2 Diabetes mellitus at least one year ago
  • Hemoglobine A1C Less than or equal to 9
  • Diabetic neuropathy with NDS(Neuropathy Disablity Score) greater than or equal to 6, VAS(Visual analogue scale)fore pain at least 4 and NSS(Neuropathy symptom score) greater than or equal to 5
  • glomerular filtration rate more than 30 cc/min

Exclusion Criteria

  • Type 1 diabetes
  • pregnancy or breastfeeding
  • Diabetic foot ulcer
  • neuropathy for reasons other than diabetes
  • History of cerebrovascular disease and discopathy
  • Use other medications to relieve symptoms of neuropathy
  • Use of alcoholic drink or opioids

Outcomes

Primary Outcomes

Not specified

Similar Trials